Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David R. Borcherding is active.

Publication


Featured researches published by David R. Borcherding.


European Journal of Pharmacology | 1996

Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-α

Charlene D. McWhinney; Mark W. Dudley; Terry L. Bowlin; Norton P. Peet; Lawrence B. Schook; Marita Bradshaw; Mamata De; David R. Borcherding; Carl K. Edwards

Murine macrophage-derived tumor necrosis factor alpha (TNF-alpha) gene expression has been shown to be dramatically induced by bacterial lipopolysaccharide, and to be dependent upon nuclear factor-kappa B (NF-kappa B) binding sites in its promoter for the lipopolysaccharide induction. Murine J774.1 macrophage cells were found to predominantly express the adenosine A3 receptor RNA relative to adenosine A1 receptor or adenosine A2 receptor RNA. Adenosine receptor agonists, in a dose-dependent manner characteristic of the adenosine A3 receptor, blocked the endotoxin induction of the TNF-alpha gene and TNF-alpha protein expression in the J774.1 macrophage cell line. The adenosine A3 receptor antagonist BW-1433 dose-dependently reversed this adenosine inhibitory effect on TNF-alpha gene expression. Thus, the binding of adenosine receptor agonists to the adenosine A3 receptor interrupts the endotoxin CD14 receptor signal transduction pathway and blocks induction of cytokine TNF-alpha, revealing a novel cross-talk between the murine adenosine A3 receptor and the endotoxin CD14 receptor in J774.1 macrophages.


Antimicrobial Agents and Chemotherapy | 1987

9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity.

Masahide Hasobe; James G. McKee; David R. Borcherding; Ronald T. Borchardt

Two synthetic analogs of neplanocin A, which were shown in a separate study to be inhibitors of S-adenosylhomocysteine hydrolase and devoid of substrate activity with adenosine kinase, were found in this study to inhibit vaccinia virus replication in murine L929 cells but to have reduced cytotoxicity compared with that of the parent compound. These results confirm that S-adenosylhomocysteine hydrolase is the molecular target which mediates the antiviral effects of neplanocin A and that transformation by cellular adenosine kinase mediates its cytotoxic properties.


Tetrahedron Letters | 1989

A 9-step enantiospecific synthesis of (−)-aristeromycin from D-ribonic acid γ-lactone

Michael S. Wolfe; David R. Borcherding; Ronald T. Borchardt

Abstract A short, efficient, enantiospecific total synthesis of (-)-aristeromycin, which can be modified for making analogues of this carbocyclic nucleoside, is reported.


Antiviral Chemistry & Chemotherapy | 1993

(1′R, 2′S, 3′R)-9-(2′, 3′-Dihydroxycyclopentan-1′-yl)-Adenine and −3-Deaza-Adenine: Analogues of Aristeromycin Which Exhibit Potent Antiviral Activity with Reduced Cytotoxicity

M. Hasobe; H. Liang; D. B. Ault-Riché; David R. Borcherding; M. S. Wolfe; Ronald T. Borchardt

Two synthetic analogues of aristeromycin, which were shown in a separate study to be inhibitors of S-adenosylhomocysteine hydrolase and devoid of substrate activity with adenosine kinase and adenosine deaminase, were found in this study to inhibit vaccinia virus replication in murine L929 cells and to have reduced cytotoxicity compared with that of the parent compound. Aristeromycin was shown to produce cytocidal effects on murine L929 cells, whereas the synthetic analogues produced cytostatic effects on cell growth. The antiviral effects of these synthetic analogues are correlated with their ability to elevate the intracellular ratio of S-adenosylhomocysteine/S-adenosylmethionine. These results confirm that S-adenosylhomocysteine hydrolase is the molecular target which mediates the antiviral effects of aristeromycin and that transformation of aristeromycin by cellular adenosine kinase mediates its cytocidal properties.


Nucleosides, Nucleotides & Nucleic Acids | 1999

The synthesis and biological activity of a highly selective adenosine A2a receptor agonist.

David R. Borcherding; Nelsen L. Lentz; Philip M. Weintraub; Mark W. Dudley; Roberta Secrest; Philip R. Kastner; Norton P. Peet

Three novel nucleosides 1, 2, and 3 were prepared that contained side chains at the 2-position of adenosine. Compound 1 was shown to be the most selective A2a receptor agonist reported to date having an A1/A2 ratio of 2400. In addition, compound 1 was shown to reduce blood pressure in rats and dogs with only minimal effects on heart rate.


Tetrahedron | 2003

Recent advances in the synthesis of piperidones and piperidines

Philip M. Weintraub; Jeffrey S. Sabol; John M. Kane; David R. Borcherding


Journal of Organic Chemistry | 1987

Synthesis of analogs of neplanocin A: utilization of optically active dihydroxycyclopentenones derived from carbohydrates

David R. Borcherding; Stephen A. Scholtz; Ronald T. Borchardt


Archive | 1999

6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines

Jennifer A. Dumont; Alan J. Bitonti; David R. Borcherding; Norton P. Peet; H. Randall Munson; Patrick Wai-Kwok Shum


Journal of Medicinal Chemistry | 2001

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717

Matthias K. Dreyer; David R. Borcherding; Jennifer A. Dumont; Norton P. Peet; Joseph T. Tsay; Paul S. Wright; Alan J. Bitonti; Jian Shen; Sung-Hou Kim


Journal of Medicinal Chemistry | 1988

Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 11. Molecular dissections of neplanocin A as potential inhibitors of S-adenosylhomocysteine hydrolase.

David R. Borcherding; Sunanda R. Narayanan; Masahide Hasobe; James G. McKee; Bradley T. Keller; Ronald T. Borchardt

Collaboration


Dive into the David R. Borcherding's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael S. Wolfe

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge